hrp0097p1-280 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

The Metabolism of 11-Oxy Androgens by Fetal CYP3A7 and CYP3A4 is Less Efficient Compared to Classical Androgens

du Toit Therina , E Flück Christa , V Pandey Amit , Groessl Michael

Steroidogenic enzyme expression in the fetal adrenal and the placenta hints at the production and metabolism of adrenal-derived 11-oxy androgens (11OxyAs) in the fetal-placental unit. Thus, 11OxyAs are present in placental tissue, fetal cord blood and neonatal serum, and could have a particular role during fetal development. The metabolism of the 11OxyAs in the fetal unit, therefore, presents as a focal point of investigation. Adrenal androgens are primarily metabolized by the...

hrp0097p1-514 | Growth and Syndromes | ESPE2023

Addition of genetic workup in children with isolated short stature to improve the diagnostic yield for growth hormone treatment

Martinez de Lapiscina Idoia , Zürcher Matthias , Saner Christoph , E. Flück Christa

Introduction: Short stature is a common finding that affects per definition about 3% of the population. Isolated, severe short stature may be treated successfully with recombinant human growth hormone (rhGH). Currently, rhGH is offered to short children with specific disorders or biochemically proven growth hormone deficiency (GHD). However, biochemical testing for GHD is artificial and therefore controversial. Adding genetic testing may improve the diagnostic...

hrp0097p1-356 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Acquired Hypothalamic dysfunction in childhood: “What do patients need?“ – an Endo-ERN survey

van Roessel I.M.A.A. , de Graaf J.P. , Biermasz N.R. , Charmandari E. , van Santen H.M.

Objective: Hypothalamic dysfunction is a rare condition and can be encountered in patients who have been diagnosed or treated for a suprasellar brain tumor. Due to its rarity, signs and symptoms of hypothalamic dysfunction may be difficult to recognize, leading to delayed diagnosis of the suprasellar brain tumor or to difficulties in finding the health care expertise for hypothalamic dysfunction after tumor treatment. To improve care and outcome of patients wi...

hrp0097p1-565 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Insights into pubertal development among individuals with NR5A1/SF-1 variants: Results from the international SF1next study

Kouri Chrysanthi , Sommer Grit , Martinez de LaPiscina Idoia , E. Flück Christa

Background: NR5A1/SF-1 variants result in a wide range of phenotypes including DSD, male infertility, and primary ovarian insufficiency (POI). Little is known of how NR5A1/SF-1 variants affect puberty in individuals with or without DSD. This study aimed to assess the impact of NR5A1/SF-1 variants on pubertal development and investigate whether abnormal puberty is linked to the severity of DSD in an international cohort with NR5A1...

hrp0097p1-566 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Inhibin A (INHA) and steroidogenic factor 1 (SF-1/NR5A1) collaborate in regulating human sex development.

Naamneh Elzenaty Rawda , Sara Sauter Kay , Kouri Chrysanthi , Martinez de Lapiscina Idoia , E. Flück Christa

Background: Inhibin consists of two homologous subunits, the α (INHA) and the βA or βB subunits (INHBA/INHBB). Both inhibins play an important role in the hypothalamic-pituitary-gonadal axis by regulating the follicle stimulating hormone levels. INHA knockout mice develop mixed or incompletely differentiated gonadal stromal tumours. In females, some INHA variants have been associated with primary ova...

hrp0095fc2.5 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Effects of burosumab treatment on mineral homeostasis in children and adolescents with X-linked hypophosphatemia: lessons from the German XLH Registry

Ewert Annika , Rehberg Mirko , Hiort Olaf , Binder Gerhard , Schröder Carmen , Jorch Norbert , Richter-Unruh Annette , Freiberg Clemens , Peter Schlingmann Karl , Haffner Dieter , Schnabel Dirk

Introduction: Burosumab was approved for treatment of pediatric patients with X-linked hypophosphatemia (XLH). However, data on its efficacy in adolescents (age > 12 years) and in real-world settings are lacking.Material and methods: Here we assess the effects of 12 months burosumab treatment on mineral homeostasis in 77 pediatric XLH patients (50 children, 27 adolescents) enrolled in the German XLH Registry. Age and ...

hrp0095fc5.5 | Adrenals and HPA Axis | ESPE2022

Influence of prenatal environment and genetic background on glucocorticoid steroid metabolism in monozygotic twins with intra-twin birthweight-differences

Schulte Sandra , Schreiner Felix , Plamper Michaela , Kasner Charlotte , Gruenewald Mathias , Bartmann Bartmann Peter , Fimmers Rolf , Hartmann Michaela F. , Wudy Stefan A. , Woelfle Joachim , Gohlke Bettina

Preliminary results:Objective: Although low birthweight (bw) and unfavourable intrauterine conditions have been associated with metabolic sequelae in later life, little is known about their impact on steroid metabolism. We studied genetically identical twins with intra-twin bw-differences from birth to adolescence to analyse the long-term impact of bw on steroid metabolism.Methods:...

hrp0095fc8.2 | Diabetes and Insulin | ESPE2022

Detection of anti-islet antibodies in capillary blood by the antibody detection by agglutination-PCR (ADAP) technology is sensitive and suitable for general population screening programs

Oron Tal , de Jesus Cortez Felipe , Shtaif Biana , Robinson Peter V. , Yackobovitch-Gavan Michal , Seftel David , Phillip Moshe , Tsai Cheng-ting , Gat-Yablonsky Galia

Background: Detection of type 1 diabetes (T1D) at the pre-clinical stage is possible by detecting islet autoantibodies (IA) years before the appearance of symptomatic diabetes. An efficient screening program based on these antibodies will identify children at risk of developing diabetes during childhood. The antibody detection Israeli research (ADIR) is a general population screening program in Israel searching for children with multiple IA who are at risk of ...

hrp0095p1-86 | Fat, Metabolism and Obesity | ESPE2022

Detailed cardiac phenotyping of obese patients with mutations in the genes POMC and MC4R

Ruck Lisa , Usadel Lea , Krabusch Philipp , Wiegand Susanna , Flück Christa , Kühne Titus , Cone Roger , Litt Michael , Helm Marcus , Kühnen Peter

Pro-opiomelanocortin (POMC) and the melanocortin-4-receptor (MC4R) are playing a key role within the leptin-melanocortin-pathway and thereby for satiety regulation. Mutations within these genes are leading to hyperphagia and early-onset obesity. However, observations of cardiac abnormalities including left ventricular dilatation and reduced contractibility in the MC4R knockout mouse model and reports about a reduced blood pressure in human MC4R variant carriers, led us to inve...

hrp0095p1-279 | Fat, Metabolism and Obesity | ESPE2022

Sex-specific POMC DNA methylation variability is associated with increased body weight

Lechner Lara , Wiegand Susanna , Leitão Elsa , Schröder Christopher , Jöckel Karl-Heinz , Nöthen Markus , Schmidt Börge , Horsthemke Bernhardt , Kühnen Peter

The increasing prevalence of obesity and associated comorbidities worldwide is a major problem for national health care systems. For this reason, it is of importance to gain knew knowledge about the central regulation of body weight and to identify factors which are leading to an increased individual risk to gain weight. Despite large genome weight associations studies and related genetic risk scores, the regulation of inter-individual body weight variability remains elusive. ...